Happy holidays! Please be advised that in-transit patient samples will be held by the carrier on Dec. 25 and received by our lab the next day. Kit orders placed on Dec. 25 will be sent on Dec. 26. Our genetic counseling services, client services, and billing services will be unavailable Dec. 24-25; please leave us a message at 888-729-1206 or support@genedx.com and we will respond when we return.
Board Member
Eli Casdin has served on the Board of Directors at GeneDx (formerly Sema4) since July 2021.
Eli founded Casdin Capital in 2011 and serves as Chief Investment Officer and Founder. Casdin Capital engages as productive investor-partners, helping to fuel the visions of industry leaders by adding expertise and experience to their funding. Focused on emergent technologies in life sciences for more than two decades, Eli has been active in both private and public capital markets, following a passion for analyzing and investing in new technologies and business models within the life sciences and healthcare industry.
Prior to Casdin Capital, Eli served as Vice President at Alliance Bernstein’s thematic investment arm, focusing personally on new technologies for the life sciences and healthcare sectors. While there, he authored the 2011 black book, “The Dawn of Molecular Medicine,” detailing the (then) early-yet-accelerating wave of innovations transforming healthcare and creating opportunity for investors from testing to targeted medicine, and diagnostics to industrial agriculture.
Earlier, Eli worked as a financial analyst at Bear Stearns and Cooper Hill Partners, a healthcare-focused investment firm.
In addition to Sema4, Eli currently serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups and academic institutes including Rockefeller University, the New York Genome Center Board, and The Columbia University School of General Studies Board of Visitors.
Eli earned a BS from Columbia University and an MBA from Columbia Business School.
